Home
NTLA
NTLA News

Latest Intellia Therapeutics Inc. (NTLA) News on October 9, 2025

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 days ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought

Motley Fool

8 days ago

Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

GlobeNewswire

17 days ago

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up

Zacks

20 days ago

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up

MT Newswires

21 days ago

Sector Update: Health Care Stocks Advance Premarket Thursday

MT Newswires

21 days ago

Intellia Therapeutics Completes Enrollment in Phase 3 Study of Potential Hereditary Angioedema Treatment

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

GlobeNewswire

21 days ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

3 Promising Genomics Stocks to Keep an Eye On in 2025

Zacks

3 months ago

3 Promising Genomics Stocks to Keep an Eye On in 2025

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

Zacks

3 months ago

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress

Insider Monkey

4 months ago

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress

Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?

Simply Wall St.

4 months ago

Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

Zacks

4 months ago

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

Investor's Business Daily

4 months ago

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential

Insider Monkey

4 months ago

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

BioPharma Dive

4 months ago

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

MT Newswires

4 months ago

Intellia Therapeutics Says Potential Hereditary Angioedema Treatment Reduces Attacks

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

GlobeNewswire

4 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Zacks

4 months ago

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%

Zacks

4 months ago

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Zacks

4 months ago

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Will Tesla have to play catch up to Waymo's robotaxis?

Yahoo Finance Video

4 months ago

Will Tesla have to play catch up to Waymo's robotaxis?

Why Scott Bessent wants to make it easier for banks to own Treasurys

Yahoo Finance

4 months ago

Why Scott Bessent wants to make it easier for banks to own Treasurys

Statement by Minister Guilbeault on Portuguese Heritage Month

CNW Group

4 months ago

Statement by Minister Guilbeault on Portuguese Heritage Month

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

PR Newswire

4 months ago

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

GlobeNewswire

4 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

GlobeNewswire

4 months ago

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

Man Utd sign Brazil forward Cunha from Wolves

AFP

4 months ago

Man Utd sign Brazil forward Cunha from Wolves

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

Moneywise

4 months ago

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

Zacks

4 months ago

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

Intellia stock dips following safety event in Phase III gene therapy trial

Clinical Trials Arena

4 months ago

Intellia stock dips following safety event in Phase III gene therapy trial

Morningstar Research

4 months ago

Analyst Report: Intellia Therapeutics, Inc.

MT Newswires

4 months ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Thursday

MT Newswires

4 months ago

Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well

Investing.com

4 months ago

Intellia stock tumbles on safety concerns

MT Newswires

4 months ago

Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating

Intellia filing spurs safety concerns over CRISPR drug

BioPharma Dive

4 months ago

Intellia filing spurs safety concerns over CRISPR drug

MT Newswires

5 months ago

Sector Update: Health Care Stocks Steady-to-Lower Pre-Bell Monday

MT Newswires

5 months ago

Top Premarket Gainers

MT Newswires

5 months ago

Intellia Therapeutics Says Drug Shows Potential in Phase 1 Transthyretin Amyloidosis Trial

GlobeNewswire

5 months ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?

Zacks

5 months ago

Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?

Analyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter Report

Simply Wall St.

5 months ago

Analyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter Report

News Flash: Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Forecasts

Simply Wall St.

5 months ago

News Flash: Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Forecasts

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

Zacks

5 months ago

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

MT Newswires

5 months ago

Truist Securities Cuts Price Target on Intellia Therapeutics to $33 From $50, Maintains Buy Rating

MT Newswires

5 months ago

RBC Trims Price Target on Intellia Therapeutics to $30 From $32, Keeps Outperform, Speculative Risk

Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

GuruFocus.com

5 months ago

Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

Morningstar Research

5 months ago

Analyst Report: Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Zacks

5 months ago

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

GlobeNewswire

5 months ago

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates

Zacks

5 months ago

CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

5 months ago

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Zacks

5 months ago

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average

Zacks

5 months ago

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

GlobeNewswire

5 months ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

5 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet

Zacks

5 months ago

Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet

Trump’s FDA Sends a Bullish Signal to Biotech

The Wall Street Journal

6 months ago

Trump’s FDA Sends a Bullish Signal to Biotech

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Investor's Business Daily

6 months ago

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

MT Newswires

6 months ago

Intellia Therapeutics Shares Rise After Upgrade From Wolfe Research

MT Newswires

6 months ago

Wolfe Research Upgrades Intellia Therapeutics to Outperform From Peer Perform, Price Target is $21

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

Insider Monkey

6 months ago

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN

Clinical Trials Arena

6 months ago

Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

Pharmaceutical Technology

6 months ago

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

GlobeNewswire

6 months ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

MT Newswires

6 months ago

RBC Cuts Price Target on Intellia Therapeutics to $32 From $37, Keeps Outperform, Speculative Risk

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?

Insider Monkey

6 months ago

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks

6 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Intellia Focuses on Pipeline Development Amid Stiff Competition

Zacks

6 months ago

Intellia Focuses on Pipeline Development Amid Stiff Competition

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication

Zacks

6 months ago

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication

MT Newswires

6 months ago

Intellia Therapeutics' Gene-Editing Drug Gets FDA Designation

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

GlobeNewswire

6 months ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

7 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls

The Fly

7 months ago

Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls

MT Newswires

7 months ago

HC Wainwright Initiates Intellia Therapeutics at Buy With $30 Price Target

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

7 months ago

Truist Securities Adjusts Intellia Therapeutics Price Target to $50 From $90, Maintains Buy Rating

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Simply Wall St.

7 months ago

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Zacks

7 months ago

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

7 months ago

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

MT Newswires

7 months ago

RBC Cuts Price Target on Intellia Therapeutics to $37 From $47, Keeps Outperform, Speculative Risk

MT Newswires

7 months ago

JPMorgan Downgrades Intellia Therapeutics to Neutral, Price Target is $13

Morningstar Research

7 months ago

Analyst Report: Intellia Therapeutics, Inc.

Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

GuruFocus.com

7 months ago

Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

Thomson Reuters StreetEvents

7 months ago

Q4 2024 Intellia Therapeutics Inc Earnings Call

MT Newswires

7 months ago

Intellia Therapeutics Q4 Net Loss Narrows; Shares Rise Pre-Bell

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Zacks

7 months ago

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire

7 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks

7 months ago

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

What's in Store for These 5 Biotech Stocks This Earnings Season?

Zacks

8 months ago

What's in Store for These 5 Biotech Stocks This Earnings Season?

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Motley Fool

8 months ago

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks

8 months ago

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?

Zacks

8 months ago

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

GlobeNewswire

8 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently

Insider Monkey

8 months ago

Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently

Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?

Zacks

8 months ago

Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?

Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025

Insider Monkey

8 months ago

Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025

Share on Social Networks: